A gene editing enzyme could be used to disable RNA viruses such as influenza or Ebola.
Researchers have decoded how the body’s immune system reacts to a poorly understood Ebola virus vaccine, and how the body generates effective antibodies against the disease.
Researchers announced the first administration to study volunteers of a vaccine candidate against Lassa fever.virus.
The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the US National Institute of Allergy and Infectious Diseases (NIAID), an institute within the US National Institutes of Health (NIH).
Integrating the technologies revolutionizing immunotherapy and its impact on vaccines development
Starting in November, doctors will use, a new Ebola virus vaccine that is better suited for broad-based prophylaxis than the existing vaccine currently being used to combat the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC).
The trial will evaluate the safety, tolerability, and immunogenicity of MVA-BN WEV in 45 healthy adults in three treatment groups receiving different doses of the vaccine.
Identifying and vaccinating Ebola patient contacts is crucial to protect people at risk and poses one of the major challenges in containing the outbreak.
The US Food and Drug Administration (FDA) has given approval of Jynneos Smallpox and Monkeypox Vaccine, Live, This is the only currently FDA-approved vaccine for the prevention of monkeypox disease.
The US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) will work with BioFactura, Inc., providing expertise and $9.5 million over two years to develop a monoclonal antibody treatment for smallpox. BARDA has options to support additional work, providing up to a total of $67.4 million over five years.